[en] BACKGROUND: We conducted a retrospective survey within the European Society for Blood and Marrow Transplantation (EBMT) registry to assess the outcomes of cord blood transplantation (CBT) in secondary acute myeloid leukemia (sAML). METHODS: Inclusion criteria consisted of >/= 18 years of age, sAML, first CBT between 2002 and 2016, and either first complete remission (CR) or active disease at CBT. RESULTS: One hundred forty six patients met the study inclusion criteria. Status at transplantation was first CR (n=97), primary refractory sAML (n=30) or relapsed (n=19) sAML. Neutrophil engraftment was achieved in 118 patients while the remaining 25 patients (17%) failed to engraft. This include 13% of patients transplanted in first CR versus 30% of those transplanted with active disease (P=0.008)). Two-year incidences of relapse were 25% in first CR patients versus 36% in those with advanced disease (P=0.06) while 2-year incidences of nonrelapse mortality were 35% and 49% (P=0.03), respectively. At 2-year overall survival, leukemia-free survival and graft-versus-host disease (GVHD)-free relapse free survival were 42% versus 19% (P<0.001), 40% versus 16% (P<0.001), and 26% versus 12% (P=0.002) in first CR patients versus those with advanced disease, respectively. CONCLUSIONS: We report here the first study of CBT in a large cohort of sAML patients. Main observation was that CBT rescued approximately 40% of patients with sAML in first CR. This article is protected by copyright. All rights reserved.
Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011; 117: 5019–32.
Zeichner SB, Arellano ML. Secondary adult acute myeloid leukemia: a review of our evolving understanding of a complex disease process. Curr Treat Options Oncol 2015; 16: 37.
Stolzel F, Pfirrmann M, Aulitzky WE et al. Risk stratification using a new prognostic score for patients with secondary acute myeloid leukemia: results of the prospective AML96 trial. Leukemia 2011; 25: 420–8.
Ramadan SM, Suciu S, Stevens-Kroef M et al. Survival improvement of secondary acute myeloid leukemia over time: experience from 962 patients included in 13 EORTC-Gimema-HOVON Leukemia Group Trials. Blood 2013; 122: 1.
Selleslag D, Suciu S, Meloni G et al. Low dose clofarabine in combination with a standard remission induction in patients 18–60 years with previously untreated intermediate and bad risk acute myeloid leukemia or high risk myelodysplastic syndrome: combined phase I/II results of the EORTC/GIMEMA AML-14A Trial. Haematologica 2017; 102: e47–51.
Amadori S, Suciu S, Selleslag D et al. Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 Trial. J Clin Oncol 2016; 34: 972–9.
Hulegardh E, Nilsson C, Lazarevic V et al. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry. Am J Hematol 2015; 90: 208–14.
Granfeldt Ostgard LS, Medeiros BC, Sengelov H et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. J Clin Oncol 2015; 33: 3641–9.
Rampal R, Ahn J, Abdel-Wahab O et al. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proc Natl Acad Sci USA 2014; 111: E5401–10.
Takahashi K, Wang F, Kantarjian H et al. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncol 2017; 18: 100–11.
Kayser S, Dohner K, Krauter J et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 2011; 117: 2137–45.
Sengsayadeth S, Labopin M, Boumendil A et al. Transplant outcomes for secondary acute myeloid leukemia: acute leukemia working party of the European society for blood and bone marrow transplantation study. Biol Blood Marrow Transplant 2018; 24: 1406–14.
Weisdorf D, Eapen M, Ruggeri A et al. Alternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: a center for international blood and marrow transplant research-eurocord analysis. Biol Blood Marrow Transplant 2014; 20: 816–22.
Ruggeri A, Sanz G, Bittencourt H et al. Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT. Leukemia 2014; 28: 779–86.
Eapen M, Rocha V, Sanz G et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol 2010; 11: 653–60.
Baron F, Labopin M, Ruggeri A et al. Impact of donor type in patients with AML given allogeneic hematopoietic cell transplantation after low-dose TBI based regimen. Clin Cancer Res 2018; 24: 2794–803.
Ustun C, Giannotti F, Zhang MJ et al. Outcomes of UCB transplantation are comparable in FLT3 + AML: results of CIBMTR, EUROCORD and EBMT collaborative analysis. Leukemia 2017; 31: 1408–14.
Milano F, Gooley T, Wood B et al. Cord-blood transplantation in patients with minimal residual disease. N Engl J Med 2016; 375: 944–53.
Ringden O, Labopin M, Ehninger G et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol 2009; 27: 4570–7.
Baron F, Labopin M, Niederwieser D et al. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. Leukemia 2012; 26: 2462–8.
Baron F, Ruggeri A, Beohou E et al. RIC versus MAC UCBT in adults with AML: a report from Eurocord, the ALWP and the CTIWP of the EBMT. Oncotarget 2016; 7: 43027–38.
Baron F, Ruggeri A, Beohou E et al. Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMT. J Hematol Oncol 2017; 10: 128.
Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295–304.
Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. Bone Marrow Transplant 2016; 51: 610–1.
Sorror ML, Maris MB, Storb R et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912–9.
Baron F, Ruggeri A, Labopin M et al. Umbilical cord blood transplantation versus unrelated donor transplantation in adults with relapsed or primary refractory acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy & Immunobiology Working Party of the EBMT. Bone Marrow Transplant 2017; 52: S80.
Li Z, Labopin M, Ciceri F et al. Haploidentical transplantation outcomes for secondary acute myeloid leukemia: Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) study. Am J Hematol 2018; 93: 769–77.
Admiraal R, Lindemans CA, van Kesteren C et al. Excellent T-cell reconstitution and survival depend on low ATG exposure after pediatric cord blood transplantation. Blood 2016; 128: 2734–41.
Pascal L, Mohty M, Ruggeri A et al. Impact of rabbit ATG-containing myeloablative conditioning regimens on the outcome of patients undergoing unrelated single-unit cord blood transplantation for hematological malignancies. Bone Marrow Transplant 2015; 50: 45–50.
Baron F, Ruggeri A, Beohou E et al. Occurrence of graft-versus-host disease increases mortality after umbilical cord blood transplantation for acute myeloid leukemia: a report from Eurocord and the ALWP of the EBMT. J Intern Med 2018; 283: 178–89.
Wagner JE Jr, Brunstein CG, Boitano AE et al. Phase I/II trial of StemRegenin-1 expanded umbilical cord blood hematopoietic stem cells supports testing as a stand-alone graft. Cell Stem Cell 2016; 18: 144–55.
Anand S, Thomas S, Hyslop T et al. Transplantation of ex vivo expanded umbilical cord blood (NiCord) decreases early infection and hospitalization. Biol Blood Marrow Transplant 2017; 23: 1151–7.
Baron F, Ruggeri A, Nagler A. Methods of ex vivo expansion of human cord blood cells: challenges, successes and clinical implications. Expert Rev Hematol 2016; 9: 1–18.
Sengsayadeth S, Gatwood KS, Boumendil A et al. Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study. Blood Adv 2018; 2: 2127–35.
Shouval R, Ruggeri A, Labopin M et al. An integrative scoring system for survival prediction following umbilical cord blood transplantation in acute leukemia. Clin Cancer Res 2017; 23: 6478–86.
Baron F, Labopin M, Ruggeri A et al. Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female unrelated cord blood-a report from Eurocord, the Acute Leukemia Working Party, and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the European Group for Blood and Marrow Transplantation. J Hematol Oncol 2015; 8: 107.
